Vitality Watch

Dossier pubmed observational 22-aug-2026
Human cohort, case-control, or epidemiological association

Ensemble DNA methylation clock demonstrates Immune-metabolic aging signatures associated with mortality.

Key claim: A stacked ensemble DNA methylation survival model built on 190 CpG sites from the Framingham Heart Study predicts all-cause mortality better than PhenoAge and comparably to GrimAge, highlighting immune-metabolic aging signatures.

Abstract

Aging is a multifactorial process that is best described in terms of the progressive acquisition of multiple layers of phenotypic changes, such as epigenetic modifications, inflammation, and metabolic dysregulation. DNA methylation clocks have been extensively used to construct epigenetic clocks based on the DNAm profiles that can be used to estimate biological age and predict age-associated outcomes. Nevertheless, the vast majority of clocks constructed so far have been based on linear models, which are unlikely to fully account for the heterogeneity and non-linearity of survival-related DNAm signatures. In this work, we constructed a heterogeneous stacked ensemble survival model based on DNAm data obtained from the Framingham Heart Study. We first identified 190 CpG loci using elastic net Cox regression and subsequently constructed a survival prediction model based on the fusion of five complementary survival models by means of a neural network meta-learner. The prediction power of the survival model was evaluated in an external validation cohort, where we observed strong performance for predicting all-cause mortality that significantly exceeded PhenoAge and was statistically comparable to GrimAge. These performance estimates were derived in cohorts of European ancestry and externally validated in postmenopausal women aged 50-79 years, and should therefore be interpreted as applicable only to demographically similar populations.

Why this matters

The second-generation DNAm clock field has been dominated by GrimAge and PhenoAge; a stacked ensemble built on Framingham data that matches GrimAge and beats PhenoAge on all-cause mortality shows the methodological ceiling for mortality-trained methylation clocks is not yet reached, but the gains are incremental. The clock’s top CpGs clustering around immune and metabolic programs reinforces that most of the mortality signal captured by blood-based methylation clocks lives in immunosenescence- and inflammaging-adjacent loci rather than being spread evenly across aging biology.

Source

Link

Briefing card

Ensemble DNA methylation clock demonstrates Immune-metabolic aging signatures associated with mortality.
Stage: observational · pubmed · 22-aug-2026

If you track your biological age via a PhenoAge-based consumer test, this analysis found a newer ensemble methylation clock predicts mortality more accurately than PhenoAge in the Framingham cohort.

A stacked ensemble DNA methylation survival model built on 190 CpG sites from the Framingham Heart Study predicts all-cause mortality better than PhenoAge and comparably to GrimAge, highlighting immune-metabolic aging signatures.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.mad.2026.112240

build build 880 · 2bcef25 · 2026-11-18